Sachetta LLC Makes New $40,000 Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

Sachetta LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 635 shares of the company’s stock, valued at approximately $40,000.

Several other hedge funds have also recently made changes to their positions in the company. Driehaus Capital Management LLC grew its position in TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after purchasing an additional 202,867 shares during the period. Principal Financial Group Inc. boosted its stake in shares of TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after buying an additional 146,115 shares during the last quarter. Public Sector Pension Investment Board acquired a new stake in TransMedics Group during the third quarter worth about $11,079,000. Connor Clark & Lunn Investment Management Ltd. raised its position in TransMedics Group by 665.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after acquiring an additional 64,872 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. lifted its holdings in TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after acquiring an additional 64,360 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $60.82 on Friday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The stock’s 50 day simple moving average is $68.65 and its 200-day simple moving average is $114.97. The company has a market cap of $2.04 billion, a PE ratio of 64.70 and a beta of 2.12. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same quarter in the previous year, the business posted ($0.12) EPS. The company’s revenue for the quarter was up 63.7% on a year-over-year basis. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. The trade was a 4.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now owns 732 shares of the company’s stock, valued at $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on TMDX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. Canaccord Genuity Group cut their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. TD Cowen cut their price target on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Finally, Piper Sandler lowered their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.